Intra-Articular Delivery of Allogeneic Bone Marrow Derived Mesenchymal Stromal Cells (BM-MSCs) for Painful Lumbar Facet Arthropathy: A Phase I Clinical Trial
Source: BMC
This open-label, single-arm Phase I clinical trial demonstrated a favorable safety profile for intra-articular administration of allogeneic, culture-expanded BM-MSCs in the treatment of painful lumbar facet arthropathy. The manufacturing and delivery of the regimen were successful for all enrolled patients. No study-related SAEs occurred during the study. Aside from the expected event of injection-site discomfort following lumbar injection, no AEs were attributed to the investigational drug.
